Clinical Trials Logo

Medical Oncology clinical trials

View clinical trials related to Medical Oncology.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02439346 Terminated - Medical Oncology Clinical Trials

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

Start date: June 15, 2015
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.

NCT ID: NCT02368951 Terminated - Medical Oncology Clinical Trials

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Start date: March 24, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express fibroblast growth factor receptor 2 (FGFR2)

NCT ID: NCT02138812 Terminated - Medical Oncology Clinical Trials

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Start date: May 9, 2014
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.